gsk201510196k3.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending October 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 
 


GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
 
In accordance with DTR 3.1.4R(1)(a) and (c) I give details of changes in the interests of the following Directors and Persons Discharging Managerial Responsibilities ('PDMR') who acquired American Depositary Shares ('ADSs') in GlaxoSmithKline plc ('GSK') at a price of $39.61 per ADS, following the re-investment of the dividend paid to shareholders on 1 October 2015.
 
 
Director/PDMR
 
 
ADSs
 
Dr M M Slaoui
 
 
1,918.567
 
 
Mr N Hirons
 
240.867
 
Mr D E Troy
 
 
1,099.657
 
 
Connected Person
 
ADSs
 
Dr K Slaoui (Connected Person to Dr M M Slaoui)
 
 
84.553
 
GSK was informed of these allocations on 16 October 2015.
 
 
V A Whyte
Company Secretary
 
19 October 2015
 



 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: October 19, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc